Vaccines Webinars 2021|Immunization Conferences 2021|Immunization online events|Vaccine Congress|Immunization Congress| vaccination Conferences |Europe | Asia-pacific|USA

Quick Links

34th World Congress on Vaccines and Immunization

Theme: Current Trends and Technologies in the Field Of Vaccines and Immunization

VACCINES CONGRESS 2021

Renowned Speakers

Helder Fernando BrÃgido Martins
Retired Senior Manager at WHO
Mozambique

Nicholas Jackson
VP Head of Global Research for Sanofi Pasteur
France

Stefania Di Marco
ADVENT - IRBM
Italy

VACCINES CONGRESS 2021

The Vaccines Conference Committee looks forward to welcoming all participants from around the world to attend the "34th World Congress on Vaccines and Immunization" June 23-24, 2021, webinar. The theme of the conference is “Current Trends and Technologies in the Field Of Vaccines and Immunization”.

The Vaccines Summit 2021 conference offers highly informative and interactive sessions to encourage the exchange of ideas across a wide range of disciplines in the field of immunization, immunization and therapeutics. The conference includes explicit keynote addresses by eminent scientists, plenary sessions, a poster competition and sessions for young researchers, symposia, workshops and exhibitions. Those chosen to present at the meeting will have the opportunity to publish a manuscript based on their presentation in the Journal of Vaccines & Immunization or its sister publication, Journal of Clinical & Cellular Immunology and Immune Research. Conference Series LLC LTD organizes more than 1000 global events including more than 300 conferences, more than 500 upcoming and previous symposia and workshops in the United States, Europe and Asia with the support of 1000 additional scientific societies and publishes more than 700 open access journals containing more than 30,000 eminent personalities, renowned scientists as members of the editorial board.

Why to attend???

Vaccines Summit 2021 aims to provide an opportunity that, together with academics around the world, focuses on learning about vaccines and immunology and its progress; this is the best opportunity to reach the largest gathering of participants from the Vaccines & Immunology community. It provides an explicit platform for presentations, distributes information, meets current and potential scientists, creates a sensation with new vaccine developments and receives name recognition at this event. World-renowned speakers, the latest techniques, developments and the latest updates in vaccines and immunology are hallmarks of this conference.

Target Audience:

Researchers & Scientists related to Vaccine R&D

Deans and Professors

Directors, CEOs, Presidents and Vice Presidents

University Faculty

Medical Schools/Colleges

Nursing Schools/Colleges

Associations and Societies related to Vaccine R&D

Vaccination Program Organizing Government and Non-government Organizations

Business Entrepreneurs

Medical Devices Manufacturing Companies

Vaccine Manufacturing Companies

Vaccine Developers and Investigators

Track 1: Vaccines

Vaccines play an essential role in the health service, especially for growing children. A vaccine is a biological preparation which confers active acquired immunity to a particular disease. A total of 26 vaccines are available, authorized by the WHO. The different vaccines are measles vaccines, rubella vaccines, cholera vaccines, meningococcal vaccines, influenza vaccines, diphtheria vaccines, mumps vaccines, mumps vaccines, tetanus, hepatitis A vaccines, pertussis vaccines, tuberculosis vaccines, hepatitis B vaccines, pneumococcal fever vaccines, typhonia vaccines Hepatitis E vaccines, vaccines polio, tick-borne encephalitis vaccines, Haemophilus influenzae type b vaccines, rabies vaccines, chickenpox and herpes zoster vaccines, human papillomavirus vaccines, rotavirus gastroenteritis vaccines, vaccines against yellow fever, vaccines against Japanese encephalitis, vaccines against malaria and dengue fever vaccines. Vaccination is the most effective method to prevent infectious diseases. This conference brings out knowledge on the highlights of the latest technologies and innovations in vaccines and immunization.

Track 2: Cancer, Malaria & TB Vaccines

Malaria continues to kill 2-3 million people a year and cause untold morbidity in around 300 to 500 million people infected each year. Malaria is considered a re-emerging disease, largely due to the spread of drug-resistant strains of parasites, the degradation of health care infrastructure, and difficulties in implementing and sustaining vector control programs in the region. many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae and P. ovale. P. falciparum is responsible for the majority of deaths and most severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5 to 10% of infected people progress to the disease 9 million new cases of tuberculosis each year 1.5 million deaths from tuberculosis each year Equivalent to 20 plane crashes of passengers every day. Tuberculosis is transmitted by adults with cavitatory disease. People infected with HIV carry a greater burden of disease. Higher risk of progression from TB infection to active disease, and worse TB morbidity and mortality, compared to older children and adults.

Track 3: HIV Vaccines

The most important advances of the last century concerned the development of protective vaccines against viruses: smallpox, polio, hepatitis, human papillomavirus (HPV) and even chickenpox. But one virus remains elusive for those who seek to create a vaccine to guard against it: HIV. Getting vaccinated early, before sexual exposure, is also effective in preventing some types of STIs. Vaccines are available to prevent human papillomavirus (HPV), hepatitis A and hepatitis B.

Track 4: Combination & Conjugate Vaccines

More and more diseases can be prevented by vaccination, but maintaining community and provider acceptance requires that the number of injections not increase. Combination conjugate vaccines represent an inevitable and important advance. This article examines the efficacy and safety of combination conjugate vaccines, including the immunological mechanisms underlying interactions between vaccine epitopes, the role of immunological memory, and correlates of immunity. Particular attention is paid to the experience of combined vaccines against each of the Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis. The implications of these results for different communities are discussed, key areas for further research are identified and the implications for post-registration surveillance are discussed.

Track 5: Vaccines against Infectious Diseases

Infectious diseases are responsible for around 25% of global mortality, especially in children under 5. Much of the burden of infectious diseases could be alleviated if appropriate mechanisms could be put in place to ensure that all children have access to basic vaccines, regardless of their geographic location or economic situation. In addition, new safe and effective vaccines should be developed for a variety of infections for which no effective preventive intervention is available or practical. The public, private and philanthropic sectors must join forces to ensure that these new or improved vaccines are fully developed and become accessible to populations in need as quickly as possible.

Track 6: DNA & Synthetic Vaccines

Scientists take many approaches to designing vaccines against a microbe. These choices are usually based on basic information about the microbe, such as how it infects cells and how the immune system responds to them, as well as practical considerations, such as the regions of the world where the vaccine would be used. . A DNA vaccine against a microbe would elicit a strong antibody response to the freely floating antigen secreted by cells, and the vaccine would also stimulate a strong cellular response against microbial antigens displayed on cell surfaces. The DNA vaccine couldn't cause the disease because it wouldn't contain the microbe, just copies of a few of its genes. In addition, DNA vaccines are relatively easy and inexpensive to design and produce. Inactivated vaccines can be composed either of whole viruses or bacteria, or of fractions of either. Fractionated vaccines are either protein-based or polysaccharide-based.

Track 7: Travel & Edible Vaccines

Travel vaccines are recommended to provide protection against diseases endemic to the country of origin or destination. They aim to protect travelers and prevent the spread of disease within and between countries. There is no single vaccination schedule that works for all travelers. Each program must be individualized according to the traveler’s previous vaccinations, his state of health and risk factors, the countries to be visited, the type and duration of the trip and the time available before departure.

Edible vaccines hold great promise as a cost-effective, easy to administer, easy to store, intrinsically safe, and socio-cultural vaccine delivery system that is easily acceptable, especially for poor developing countries. This involves the introduction of selected desired genes into plants and then the induction of those modified plants to make the encoded proteins.

Track 8: Paediatric Vaccination

Vaccination against diseases such as polio, tetanus, diphtheria and pertussis saves the lives of around three million children each year. Immunization also prevents many more millions of people from suffering from debilitating diseases and lifelong disability. Around the world, approximately 132 million babies need to be fully immunized each year. To meet this need, immunization systems must have adequate resources, trained and motivated staff, and sufficient vaccines and syringes.

Track 9: Vaccines for Immune Mediated Diseases

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis have an increased risk of infection, in part due to the disease itself, but mainly due to treatment with immunosuppressive or immunosuppressive drugs. Despite their high risk of vaccine-preventable disease, vaccine coverage in IMID patients is surprisingly low. Although the reduced quality of the immune response in patients receiving immunotherapy may negatively impact the efficacy of vaccination in this population, an adequate humoral response to vaccination in IMID patients has been demonstrated for vaccination against hepatitis B, influenza and pneumococcus.

Track 10: Vaccines against Drugs‎

Drug addiction is a serious problem in the world. One therapy being studied is vaccination against drug abuse. Antibodies raised against the drug can absorb the drug and prevent it from reaching reward centers in the brain. Few such vaccines have entered clinical trials, but research continues at a rapid pace. Many studies are very promising and more clinical trials are expected to come out in the near future.

Track 11: Vaccines & Autism

Vaccinations can be one of the triggers for autism. Substantial data demonstrate an immune abnormality in many autistic children consistent with reduced resistance to infection, activation of the inflammatory response and autoimmunity. Weakened resistance may predispose to vaccine injury in autism. A mercurial preservative in childhood vaccines, thimerosal, can cause direct neurotoxic, immunosuppressive and autoimmune damage and contribute to the early onset and regression of autism. Live measles, mumps, and rubella (MMR) viruses can lead to chronic infection of the gut and trigger autism regression. Thimerosal injection may potentiate MMR lesions.

Track 12: Vaccine Safety & Efficacy

Vaccine efficacy refers to the ability of vaccines to produce the desired beneficial effects on vaccinated individuals in a defined population under ideal conditions of use. The potential benefits of an effective vaccine - eg. the promotion of health and well-being, as well as the protection against the disease and its physical, psychological and socio-economic consequences must be weighed against the potential risk of adverse event following vaccination (AEFI) with this vaccine. The risk associated with the vaccine is the likelihood of an unwanted or undesirable outcome occurring, and the severity of the resulting damage to the health of those vaccinated in a defined population following immunization with a vaccine under ideal conditions.

Track 13: Geriatric Immunization

As we age, our immune systems tend to weaken over time, putting us at higher risk for certain diseases. Therefore, in addition to the seasonal influenza (influenza) vaccine and the Td or Tdap (tetanus, diphtheria and pertussis) vaccine, adults 60 years of age or older should take pneumococcal vaccines, which protect against pneumococcal disease, including lung and bloodstream infections (also recommended for adults under 65 who have certain chronic health conditions) and the shingles vaccine, which protects against shingles.

Track 14: Vaccines for Pregnant Women & Neonates

Vaccination during pregnancy has the potential to protect mother and child against vaccine-preventable diseases. Newborns are at high risk of serious illness and death from certain infectious diseases because their immune systems are not fully developed. One of the goals of immunizing pregnant women is to increase the amount of maternal antibodies (disease-fighting proteins) transferred to infants, potentially protecting them from infectious diseases.

Track 15: Vaccines for Unconventional Diseases

It is interesting to examine the activities of drug developers in the field of vaccines inducing antibodies against non-infectious diseases and certain unconventional indications. These vaccines have in most cases been developed so far as treatment vaccines. This is the opposite of infectious disease vaccines used as prophylactic vaccines. Despite promising candidates at an advanced stage, with some very recent failures, there is still no approved antibody-inducing vaccine targeting other than antigens of microorganisms (i.e. targeting auto- antigens, antigens of dependency molecules etc. It is interesting to take a look at the activities of drug developers in the field of vaccines inducing antibodies against non-infectious diseases and certain unconventional diseases.

Track 16: Animal Models & Clinical Trials

Human vaccine development continues to rely on the use of animals for research. Regulatory authorities require that new vaccine candidates undergo preclinical evaluation in animal models before they are allowed to enter the clinical phase in human subjects. Substantial progress has been made in recent years in reducing and replacing the number of animals used for preclinical vaccine research through the use of bioinformatics and computational biology to design new vaccine candidates. However, the ultimate goal of a new vaccine is to instruct the immune system to elicit an effective immune response against the pathogen of interest, and no alternative to the use of live animals currently exists. For the evaluation of this response.

Track 17: Animal & Plant Derived Vaccines

It has been about 30 years since the first factory engineering technology was created. While the concept of pharmaceuticals or herbal vaccines motivates us to develop feasible commercial products using plant engineering, there are some challenges in achieving the end goal: to produce an approved product. Currently, the only plant-derived vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in cells of tobacco grown in suspension. Progress towards commercialization of herbal vaccines takes a great deal of effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of herbal vaccines and provides an overview of human and animal vaccines currently in clinical trials.

Track 18: Vectors, Adjuvants & Delivery Systems

A vaccine adjuvant is an ingredient in a vaccine that helps create a stronger immune response in the patient's body. In other words, adjuvants help vaccines work better. Some vaccines made from weakened or dead germs contain natural adjuvants and help the body produce a strong protective immune response. However, most vaccines developed today contain only small components of the germs, such as their proteins, rather than the whole virus or bacteria. These vaccines often need to be prepared with adjuvants to ensure that the body produces an immune response strong enough to protect the patient from the germ it is being vaccinated against. Aluminum gels or aluminum salts are vaccine ingredients that have been used in vaccines since the 1930s. Small amounts of aluminum are added to help the body build its immunity to the germ in the vaccine. Aluminum is one of the most common metals in nature and is found in air, food and water. The amount of aluminum in vaccines is low and is regulated by the United States Food and Drug Administration (FDA).

Track 19: Vaccine Production & Development

Vaccine development is an activity that focuses on a variety of technological and applied research initiatives, which improve and promote improved systems and practices for vaccine safety. Over the past year, the unprecedented Ebola outbreak has galvanized industry research and response, and as we continue to seek solutions, we must revisit lessons learned in order to overcome current challenges. . Vaccine development is a long and complex process, often lasting 10 to 15 years and involving a combination of public and private participation. The current system of vaccine development, testing and regulation developed during the 20th century, as the groups involved standardized their procedures and regulations.

Track 20: Cellular Immunology & Latest Innovations

The response to pathogens is made up of the complex interactions and activities of the large number of diverse cell types involved in the immune response. The innate immune response is the first line of defense and occurs soon after exposure to pathogens. It is carried out by phagocytic cells such as neutrophils and macrophages, natural killer cytotoxic (NK) cells and granulocytes. The subsequent adaptive immune response includes antigen-specific defense mechanisms and may take days to develop. Cell types critical to adaptive immunity are antigen presenting cells, including macrophages and dendritic cells. Antigen-dependent stimulation of various cell types, including T cell subsets, B cells, and macrophages, all play essential roles in host defense.

Track 21: Fish & Poultry Vaccines

Vaccines developed for aquaculture have reduced the use of antibiotics in fish production. Currently, vaccines are available for some economically important bacteria and only a few vaccines against viral diseases and no vaccine has been developed for parasites and fungi of fish. The main limitations of fish vaccine developments are a lesser understanding of fish immunology, many unauthorized vaccines, unprofitable (expensive) and stressful for administration. Research is needed to examine the current state of fish vaccination to control fish diseases, and to show the needs and directions for future investigations.

Vaccination plays an important role in the health management of the poultry flock. There are many diseases that are prevented by vaccinating birds against them. A vaccine helps prevent a particular disease by triggering or stimulating the bird's immune system to produce antibodies which, in turn, fight off the invading causative organisms.

Track 22: Antibodies: Engineering & Therapeutics

Antibodies, also called immunoglobulins, are large Y-shaped proteins that work to identify and help remove foreign antigens or targets such as viruses and bacteria. Antibodies are produced by specialized white blood cells called B lymphocytes (or B cells). When an antigen binds to the surface of B cells, it stimulates the B cell to divide and mature into a group of identical cells called a clone. Mature B cells, called plasma cells, secrete millions of antibodies into the bloodstream and lymphatic system. Each different antibody recognizes a specific foreign antigen. This is because the two ends of its "Y" are specific to each antigen, allowing different antibodies to bind to different foreign antigens. Antibodies are produced by the immune system in response to the presence of an antigen. Antibody engineering has become a well-developed discipline, encompassing discovery methods, production strategies, and modification techniques that have resulted in clinically studied and commercialized therapies. Achieving the long-standing goal of producing fully human monoclonal antibodies has focused intensive research on the clinical use of this potent class of drugs.

Track 23: Current Research & Future Challenges

The development of vaccines remains difficult because of the very sophisticated mechanisms of escape of pathogens for which vaccines are not yet available. Recent years have witnessed both successes and failures in the design of new vaccines, and the strength of iterative approaches is increasingly appreciated. These combine the discovery of new antigens, adjuvant and vectors at the preclinical stage with computer analyzes of clinical data to accelerate vaccine design. Reverse and structural vaccinology has revealed new antigenic candidates and molecular immunology has led to the formulation of promising adjuvant. Gene expression profiles and immune parameters in patients, vaccines and healthy controls formed the basis of the biosignatures that will provide guidelines for future vaccine design.

Abstract Submission Criteria and Eligibility

PRESENTATION REQUIREMENTS:

Participating authors are responsible for registration, travel and hotel costs.

Note: Those who submitted abstracts will receive an acknowledgment email allowing them to register for the gathering.

Abstracts will be compiled, and conference books will be made available to conference participants.

Any presenter who is unable to attend should arrange for another qualified person to present the paper / poster in question. If such a change is required, please let our conference team knows.

SUBMISSION OPTIONS:

Oral paper introductions will have 30-minute schedule time slot. The keynote session will have for 45-minute presentation duration, workshop/special session will have 1-hour long schedule opening and symposium will have 1-hour long availability followed by 5-minute Q&A session.

Graduate and master’s understudies are qualified to present their abstracts under poster and e-poster presentation category.

Ph.D. understudies are qualified to submit their abstract under special YRF (Young Researcher's Forum), poster and e-poster presentation category.

NOTE: YRF category includes short oral presentation especially for Ph. D. students

Extended abstract: Submissions should utilize the Abstract Template. Papers submitted in this category may represent original empirical research, theoretical development, reviews, or critiques.

Market Analysis:

The Vaccines & Immunization conference welcomes attendees, presenters and exhibitors from all over the world. We are delighted to invite all of you to participate and register for the "34th World Congress on Vaccines and Immunization"

The organizing committee is preparing for an exciting and informative conference program comprising plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the “34th World Congress on Vaccines and Immunization,” where you will be sure to have meaningful experience with academics from around the world. All members of the organizing committee look forward to meeting you in Rome, Italy.

Vaccine Market Overview - 2027:

The global vaccine market size was $ 32,462 million in 2019 and is expected to reach $ 54,150 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

Vaccines, also called immunizations, inject a weakened form of a disease into a person so that the body begins to produce antibodies or immunity to the disease. Effective vaccination has eradicated a number of diseases, such as polio and smallpox, with high death rates. Vaccinations play a crucial role in maintaining the sustainable health of people in different countries; therefore, they are used in various regional disease prevention strategies. The demand for vaccines has increased in recent years, due to the increasing incidence of infectious viral and bacterial diseases. Vaccinations are mainly given to people of different age groups, which strengthen their immune systems throughout life and provide protection against different types of infectious diseases.

Due to the COVID-19 pandemic, the majority of healthcare, pharmaceutical, and biotech organizations have focused on diagnostic kits, wearable safety devices, and treatment vaccines and drugs for the novel corona virus. Most major companies are focused on finding a breakthrough vaccine against the Novel corona virus. In addition, healthcare professionals are engaged in the provision of services related to COVID-19. As a result, other segments of health care must cope with neglect. Additionally, pharmaceutical companies are prioritizing the research and development of COVID-19-related diagnostics, treatments, health technologies and vaccines, as well as the potential of existing treatments. All of these factors are also expected to impact the global vaccine market in the future.

The increased investment in the development of new vaccines is expected to boost the global vaccine market in the coming years. For example, researchers at Scripps Research Florida have successfully developed a non-traditional vaccine to defeat the SIVmac239 viral strain dubbed "the death star." The unconventional vaccine developed by the researchers provides long-lasting protection to uninfected people against multiple forms of HIV driving demand for the vaccine. In addition, the increasing incidence of various infectious diseases and the growing awareness of early disease diagnosis and prevention are driving the demand for protective vaccines; thus, stimulating the growth of the market.

Several efforts by organizations, including UNICEF, have increased uptake of the vaccine over the years. The Pan American Health Organization's (PAHO) revolving fund and the influence of UNICEF's supply division make it possible to purchase vaccines at lower prices for various countries. Each year, PAHO and UNICEF purchase vaccines for nearly 40 states and about 100 countries, respectively; which has a positive impact on the adoption rate.

Vaccination helps prevent nearly 2 to 3 million deaths from various diseases, including influenza, tetanus, diphtheria, measles, whooping cough and others. In addition, according to the WHO, more than 1.5 million deaths can be prevented by improving global immunization coverage. In 2018, around 116.3 million children under one year of age received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide. As vaccine delivery increases, vaccine activity will expand dramatically over the next few years.

Limited vaccination coverage coupled with prohibitive costs of transporting and storing vaccines will negatively impact the expansion of the industry to some extent in the near future. In addition, strict government regulations for product approval will prolong the process of introducing new products to the market; which is slowing the growth of the vaccine market.

Vaccines Summit 2019 Report:

The “32nd International Conference on Vaccines and Immunization” was organized greatly, during March 21-22, 2019 at Hotel Holiday Inn, Aurelia Rome, Italy.

The conference was organized around the theme “Highlights of latest technologies and innovations in Vaccines and Immunization” which comprised of 20 Tracks designed to offer comprehensive sessions that address current issues in the field of Vaccine and Immunology. This world congress conference brought eminent scientists together from all the nations and in which many critical issues were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided a best platform for the young researchers to share their ideas and experiences.

It’s really an honor to have the speakers from all over the world and it’s been a great moment to hear on different research papers at the time of oral presentations and also young research fellows has given a great talk about the current impacts on Vaccine and immunology. Finally, the program has been closed with panel discussion and certificate distribution.

How Black faith leaders help their communities get vaccinated.

As vaccines become more readily available in the United States, attention has shifted to the task of getting as many people vaccinated as possible.

However, improving vaccination rates in black communities can be particularly difficult, according to the authors of an article published in the Lancet Global Health Trusted Source.

The paper proposes a three-tier model for improving immunization rates in black communities. It's an idea that is supported by the results of a testing program targeted at the historically underserved black community of San Bernardino County, southern California.

This campaign led to the establishment of a mobile vaccination clinic in the parking lot of a church in San Bernardino. During the one-day event, the clinic vaccinated 417 people, 84% of whom were black.

The paper also reports that targeted education efforts have led to an improvement in the percentage of black individuals who take advantage of local mass vaccination clinics after the program. Their participation increased from 3% to 3.6% in the week following the vaccination event of the mobile clinic.

Multiple states open vaccines to all adults.

As many experts fear a fourth wave, several states have extended vaccine eligibility to anyone 16 years of age or older. While some areas may struggle to cope with the influx of newly eligible people, some experts worry that people with chronic conditions may be left behind.

In some states, such as Texas and Kansas, the appointment windows for current vaccines are not occupied. This expansion of eligibility could help boost their broken immunization program.

States that open immunization slots for anyone 16 years of age or older on Monday are Texas, Oklahoma, Louisiana, Ohio, North Dakota and Kansas.

Other states - including Indiana, South Carolina, Connecticut, Montana, Hampshire and Colorado - will join them later in the week.

Some areas of Illinois also extend eligibility if doses are not used.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	June 23-24, 2021
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

34^th World Congress on Vaccines and Immunization June 23-24, 2021 Osaka,

Recommended Global Immunology Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.